pharmaphorum November 14, 2025
Anglo-Swiss life sciences investment company Medicxi has raised €500 million (around $579 million) for its sixth fund, which will focus on supporting ‘asset-centric’ companies at all stages of drug development.
The new Medicxi V fund will concentrate on “building and backing innovative biotechnology companies with clear product visions to transform patient care,” said the firm in a statement, adding that it will be used for both “drug hunters and entrepreneurs” setting up new companies and existing companies that align with its strategy.
The oversubscribed raise comes two years after Medicxi €400 million for its Medicxi IV fund, and takes the total raised by the company over the last 10 years to more than €2 billion.
Since fund IV, it has...
Today's Sponsors
Today's Sponsor